Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-1473 for Moderately-to-Severely Active Ulcerative Colitis (Phase 2b/3 Induction and Maintenance)
2018-002136-24Phase 2Terminated
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of izencitinib in autoimmune colitis (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Change in total Mayo score from baseline at Week 8 (Phase 2b induction). Started Dec 2018; status: terminated.
02
Drugs
izencitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-002136-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002136-24.